With the reshuffle of the CEO, CTO and CFO roles, I wonder if we have a consensus on the true meaning of the changes?
I note the following from Doug Wilson in BioSpectrum:
"Dr Wilson noted the company management structure had been reorganized to position it for the on-going contractual obligations and emerging strategic opportunities".
I am reminded of the quotes at the time of the appointment of Griffin Securities:
Mr Stecyk said that, "We look forward to exploring the variety of strategic options that could significantly build shareholder value including: broad therapeutic discovery alliances; partnerships spanning other applications of the platform such as animal health, agriculture and industrial; and, strategic opportunities with companies with synergistic technology."
There must be some interesting perspectives on all of this.
With the reshuffle of the CEO, CTO and CFO roles, I wonder if we...
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $629.9M | |||
| Open | High | Low | Value | Volume |
| 13.5¢ | 13.5¢ | 12.5¢ | $919.8K | 7.025M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12715 | 13.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.5¢ | 276517 | 3 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| PYC (ASX) Chart |